Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data

A. Tartarone, G. Romano, R. Galasso, G. Iodice, G. D'Arena, M. Coccaro, A. Bochicchio, A. Sgambato, N. Di Renzo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Data from eight randomised trials on high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) have been published, but only seven studies are evaluable after the Bezwoda trial was discredited. Moreover, overall survival (OS) has been evaluated in only four out of seven studies since three had a crossover design. OS was similar for the HDC and standard-dose chemotherapy (SDC) group in the four evaluable trials, while disease-free survival (DFS) was improved in the HDC group in six of the seven trials. The delay in relapse for patients with metastatic disease represents an important clinical outcome; furthermore, since none of the reported studies randomised more than 220 patients, their statistical power may have been too limited to detect meaningful survival differences. Finally, preliminary experiences have shown that HDC seems to be the ideal platform upon which to build novel therapies. In conclusion, HDC remains an important field of clinical research for breast cancer patients with stage IV disease and, from the studies reported in this article, there is some evidence for offering this therapeutic modality to selected patients who are interested in a medically aggressive approach.

Original languageEnglish
Pages (from-to)525-530
Number of pages6
JournalBone Marrow Transplantation
Volume31
Issue number7
DOIs
Publication statusPublished - Apr 2003

Fingerprint

Breast Neoplasms
Drug Therapy
Survival
Cross-Over Studies
Disease-Free Survival
Recurrence
Therapeutics
Research

Keywords

  • High-dose chemotherapy
  • Metastatic breast cancer

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data. / Tartarone, A.; Romano, G.; Galasso, R.; Iodice, G.; D'Arena, G.; Coccaro, M.; Bochicchio, A.; Sgambato, A.; Di Renzo, N.

In: Bone Marrow Transplantation, Vol. 31, No. 7, 04.2003, p. 525-530.

Research output: Contribution to journalArticle

Tartarone, A. ; Romano, G. ; Galasso, R. ; Iodice, G. ; D'Arena, G. ; Coccaro, M. ; Bochicchio, A. ; Sgambato, A. ; Di Renzo, N. / Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data. In: Bone Marrow Transplantation. 2003 ; Vol. 31, No. 7. pp. 525-530.
@article{11e3cb59a3a8469292a4d22461606196,
title = "Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data",
abstract = "Data from eight randomised trials on high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) have been published, but only seven studies are evaluable after the Bezwoda trial was discredited. Moreover, overall survival (OS) has been evaluated in only four out of seven studies since three had a crossover design. OS was similar for the HDC and standard-dose chemotherapy (SDC) group in the four evaluable trials, while disease-free survival (DFS) was improved in the HDC group in six of the seven trials. The delay in relapse for patients with metastatic disease represents an important clinical outcome; furthermore, since none of the reported studies randomised more than 220 patients, their statistical power may have been too limited to detect meaningful survival differences. Finally, preliminary experiences have shown that HDC seems to be the ideal platform upon which to build novel therapies. In conclusion, HDC remains an important field of clinical research for breast cancer patients with stage IV disease and, from the studies reported in this article, there is some evidence for offering this therapeutic modality to selected patients who are interested in a medically aggressive approach.",
keywords = "High-dose chemotherapy, Metastatic breast cancer",
author = "A. Tartarone and G. Romano and R. Galasso and G. Iodice and G. D'Arena and M. Coccaro and A. Bochicchio and A. Sgambato and {Di Renzo}, N.",
year = "2003",
month = "4",
doi = "10.1038/sj.bmt.1703824",
language = "English",
volume = "31",
pages = "525--530",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data

AU - Tartarone, A.

AU - Romano, G.

AU - Galasso, R.

AU - Iodice, G.

AU - D'Arena, G.

AU - Coccaro, M.

AU - Bochicchio, A.

AU - Sgambato, A.

AU - Di Renzo, N.

PY - 2003/4

Y1 - 2003/4

N2 - Data from eight randomised trials on high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) have been published, but only seven studies are evaluable after the Bezwoda trial was discredited. Moreover, overall survival (OS) has been evaluated in only four out of seven studies since three had a crossover design. OS was similar for the HDC and standard-dose chemotherapy (SDC) group in the four evaluable trials, while disease-free survival (DFS) was improved in the HDC group in six of the seven trials. The delay in relapse for patients with metastatic disease represents an important clinical outcome; furthermore, since none of the reported studies randomised more than 220 patients, their statistical power may have been too limited to detect meaningful survival differences. Finally, preliminary experiences have shown that HDC seems to be the ideal platform upon which to build novel therapies. In conclusion, HDC remains an important field of clinical research for breast cancer patients with stage IV disease and, from the studies reported in this article, there is some evidence for offering this therapeutic modality to selected patients who are interested in a medically aggressive approach.

AB - Data from eight randomised trials on high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) have been published, but only seven studies are evaluable after the Bezwoda trial was discredited. Moreover, overall survival (OS) has been evaluated in only four out of seven studies since three had a crossover design. OS was similar for the HDC and standard-dose chemotherapy (SDC) group in the four evaluable trials, while disease-free survival (DFS) was improved in the HDC group in six of the seven trials. The delay in relapse for patients with metastatic disease represents an important clinical outcome; furthermore, since none of the reported studies randomised more than 220 patients, their statistical power may have been too limited to detect meaningful survival differences. Finally, preliminary experiences have shown that HDC seems to be the ideal platform upon which to build novel therapies. In conclusion, HDC remains an important field of clinical research for breast cancer patients with stage IV disease and, from the studies reported in this article, there is some evidence for offering this therapeutic modality to selected patients who are interested in a medically aggressive approach.

KW - High-dose chemotherapy

KW - Metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0038369910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038369910&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703824

DO - 10.1038/sj.bmt.1703824

M3 - Article

C2 - 12692616

AN - SCOPUS:0038369910

VL - 31

SP - 525

EP - 530

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -